Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Clinical trial NCT06682169 · RECRUITING
Trial details
- NCT number
- NCT06682169
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-20
- Primary completion
- 2029-10-01
- Enrollment
- 182
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.